Biocon inks trial research pact with Spaulding; Canada approves hep C drug Incivek; artifical "skin" is bulletproof;

@FierceBiotech: A group of researchers hope to grow spare heart parts from embryonic stem cells within 5 years. Report | Follow @FierceBiotech

@JohnCFierce: Fresh off the Zelboraf win, Roche CEO Schwan does the visionary thing on pharma's bright future. Story | Follow @JohnCFierce

@RyanMFierce: A computerized blueprint for starving cancer cells: Group created the first genome-scale model of cancer cell. Item | Follow @RyanMFierce

@MaureenFierce: New way to treat C. difficile? Drug stimulates cells in the gut that can neutralize toxins. Report | Follow @MaureenFierce

> India's Biocon has forged a pact with Spaulding Clinical Research to offer clinical trial services to biotech companies. Item

> Malaysia's biotech development agency is seeking new funds to back drug developers doing late-stage work. Story

> Canadian officials have approved Vertex's new hep C drug Incivek. Report

Pharma News

@FiercePharma: On top of 280 Irish jobs saved in Pfizer plant buyout. RT @lisamjarvis: Amgen to add Dublin plant, creating 100 jobs: Report | Follow @FiercePharma

> Boehringer unit to exit contract manufacturing. Report

> Seattle Genetics prices Adcetris above $100K. Article

> U.S. officials, docs step into drug-shortage fray. Item

Biotech IT News

> Perfect algorithm proves elusive for DREAM teams. More

> A computerizing blueprint for starving cancer. Article

> Computational method rapidly discovers new uses for approved drugs. Details

> Vital models emerging to enable personalized cancer care. Report

> Deloitte grabs drug regulatory tech in new buyout. News

Medical Device News

> TheraSolve closes first financing round. Report

> Sources: Kinetic recieves higher buyout offer. Details

> Report: Medrad to buy Pathway for $125M. News

> Intersect ENT CEO discusses Propel implant. More

> Tangent taps Accuri, HandyLab vet as CEO. Story

And Finally... A researcher in Utah has been developing bulletproof "skin" made from silk and milk from transgenic goats. Story

Suggested Articles

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.

Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.